Physician profile
Robert Keller
NPI 1154760866
$45,009.29
in general payments reported to CMS, 2019-2025
20 companies · $18K in 2025
The $18K reported for 2025 was more than what 98% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $476 · 2020: $2,798 · 2021: $6,928 · 2022: $5,447 · 2023: $2,877 · 2024: $8,874 · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Food and Beverage: $1,855 · Travel and Lodging: $1,389 · Consulting Fee: $1,344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,772.63 |
| Food and Beverage | $1,854.53 |
| Travel and Lodging | $1,389.07 |
| Consulting Fee | $1,344.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $34,093.28 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $7,849.39 | 2020-2025 | Dupixent |
| Stryker Corporation | $1,059.99 | 2019-2024 | Audion Et Dilation System, Vsp System, Vsp Cranial |
| Astrazeneca Pharmaceuticals Lp | $572.24 | 2019-2025 | Tezspire |
| Medtronic, INC. | $382.84 | 2022-2025 | Propel |
| Glaxosmithkline, LLC. | $262.96 | 2019-2025 | Nucala |
| Inspire Medical Systems, INC. | $199.54 | 2021-2024 | Inspire |
| Aerin Medical INC. | $123.64 | 2019-2025 | |
| Intersect Ent, INC. | $99.07 | 2021 | |
| Neurent Medical Limited | $85.79 | 2024-2025 | Neuromark Radiofrequency Console, Neuromark System, Neuromark Device |
| Optinose US, INC. | $72.02 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.91 | 2023-2024 | Takhzyro |
| Octapharma USA, INC. | $34.70 | 2019-2020 | |
| Amgen INC. | $28.07 | 2025 | Tezspire |
| Agiliti Surgical, INC. | $24.78 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Innovation Technologies INC | $19.95 | 2024 | Irrisept |
| Shire North American Group INC | $17.54 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.50 | 2021 | |
| Cochlear Americas | $14.42 | 2024 | Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Osia Osi300 Implant, Baha |
| Hologic Sales and Service, LLC | $13.66 | 2024 | Coolseal Generator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Keller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.